ASAnne B. Satterthwaite

Anne B. Satterthwaite

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Anne B. Satterthwaite has a total of 40 co-authors. Here are the top co-authors by number of shared publications:

  • Kristina E. Halcomb

    Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA

    5 shared publications
  • Kristina Ottens

    Department of Internal Medicine, University of Texas (UT) Southwestern Medical Center, Dallas, TX, United States

    4 shared publications
  • Rochelle M. Hinman

    Rheumatic Diseases Division, Department of Internal Medicine, The University of Texas Southwestern Medical Center , Dallas, TX 75390

    4 shared publications
  • Toni Gutierrez

    Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX 75390-8884, USA

    4 shared publications
  • Cristina M. Contreras

    Department of Internal Medicine, University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Boulevard, Dallas, TX 75390, USA

    3 shared publications
  • Brian Skaug

    Rheumatic Diseases Division, Department of Internal Medicine, The University of Texas Southwestern Medical Center , Dallas, TX 75390

    2 shared publications

Latest Publications

  • Open Access

    B-1 cells contribute to increased total IgM and shape IgG autoreactivity profiles in Lyn-/- mice but are not a major source of lupus-associated pathogenic autoantibodies

    by Kristina Ottens, Anne B. Satterthwaite

    Introduction: Systemic lupus erythematosus is an autoimmune disease in which pathogenic autoantibodies targeting nucleic acid containing antigens promote inflammation and tissue damage. Recent reports suggest that deep B cell depletion will be a highly effective therapeutic strategy for lupus. However, elimination of all B cells confers susceptibility to infection. Thus, an approach which targets pathogenic B cells but spares protective ones would be ideal. The B-1 subset of B cells has been suggested to be either pathogenic or protective in lupus, depending on the study. Methods: We used several complementary approaches to define the contribution of B-1 cells to autoantibody production and immune cell activation in the Lyn-/- mouse model of lupus. We labeled activated B-1 cells to track their cellular and antibody progeny. Activated B-1 cells were also depleted or prevented from differentiating into plasma cells. Results: B-1 cells contributed significantly to the accumulation of splenic plasma cells and total IgM characteristic of Lyn-/- mice in a manner at least partially independent of the transcription factor IRF4. Unlike T-bet+ B cells, they were not a major source of pathogenic lupus-associated autoantibodies. Rather, they limited both the production of IgG against other autoantigens and the activation of CD8+ T cells. Conclusion: These studies highlight a regulatory role for B-1 cells in shaping adaptive immune tolerance in the Lyn-/- lupus model.


  • Open Access

    B-1a Cells, but Not Marginal Zone B Cells, Are Implicated in the Accumulation of Autoreactive Plasma Cells in Lyn−/− Mice

    by Kristina Ottens, Jalyn Schneider, Anne B. Satterthwaite

    Mice deficient in Lyn, a tyrosine kinase that limits B cell activation, develop a lupus-like autoimmune disease characterized by the accumulation of splenic plasma cells and the production of autoantibodies. Lyn−/− mice have reduced numbers of marginal zone (MZ) B cells, a B cell subset that is enriched in autoreactivity and prone to plasma cell differentiation. We hypothesized that this is due to unchecked terminal differentiation of this potentially pathogenic B cell subpopulation. However, impairing MZ B cell development in Lyn−/− mice did not reduce plasma cell accumulation or autoantibodies, and preventing plasma cell differentiation did not restore MZ B cell numbers. Instead, Lyn−/− mice accumulated B-1a cells when plasma cell differentiation was impaired. Similar to MZ B cells, B-1a cells tend to be polyreactive or weakly autoreactive and are primed for terminal differentiation. Our results implicate B-1a cells, but not MZ B cells, as contributors to the autoreactive plasma cell pool in Lyn−/− mice.


  • TLR7 Signaling in Lupus B Cells: New Insights into Synergizing Factors and Downstream Signals

    by Anne B. Satterthwaite

    Purpose of the Review Systemic lupus erythematosus (SLE) is driven by nucleic acid-containing antigens that stimulate endosomal TLRs. We review new advances in our understanding of how TLR7 signaling in B cells drives autoimmunity. Recent Findings Pathogenic B cell responses to TLR7 engagement are shaped by the disease-associated cytokine environment. TLR7, IFNγ, and IL-21 together promote the formation of autoreactive germinal centers and the ABC/DN2 B cell subset. BAFF and type 1 IFNs enhance autoantibody production from transitional B cells in concert with TLR7. TLR7 signaling components STAT1, BANK1, IRF5, SLC15A4, and CXorf21/TASL are associated genetically with SLE and important for lupus development in mice, while role of T-bet is controversial. Proper control of TLR7 trafficking by UNC93B1, syntenin-1, and αvβ3 integrin is critical for preventing autoimmunity. Summary A better understanding of TLR7 signaling has revealed potential new therapeutic approaches for SLE, several of which are being tested in animal models or clinical trials.


  • Open Access

    IRF4 Has a Unique Role in Early B Cell Development and Acts Prior to CD21 Expression to Control Marginal Zone B Cell Numbers

    by Kristina Ottens, Anne B. Satterthwaite

    Strict control of B lymphocyte development is required for the ability to mount humoral immune responses to diverse foreign antigens while remaining self-tolerant. In the bone marrow, B lineage cells transit through several developmental stages in which they assemble a functional B cell receptor in a stepwise manner. The immunoglobulin heavy chain gene is rearranged at the pro-B stage. At the large pre-B stage, cells with a functional heavy chain expand in response to signals from IL-7 and the pre-BCR. Cells then cease proliferation at the small pre-B stage and rearrange the immunoglobulin light chain gene. The fully formed BCR is subsequently expressed on the surface of immature B cells and autoreactive cells are culled by central tolerance mechanisms. Once in the periphery, transitional B cells develop into mature B cell subsets such as marginal zone and follicular B cells. These developmental processes are controlled by transcription factor networks, central to which are IRF4 and IRF8. These were thought to act redundantly during B cell development in the bone marrow, with their functions diverging in the periphery where IRF4 limits the number of marginal zone B cells and is required for germinal center responses and plasma cell differentiation. Because of IRF4’s unique role in mature B cells, we hypothesized that it may also have functions earlier in B cell development that cannot be compensated for by IRF8. Indeed, we find that IRF4 has a unique role in upregulating the pre-B cell marker CD25, limiting IL-7 responsiveness, and promoting migration to CXCR4 such that IRF4-deficient mice have a partial block at the pre-B cell stage. We also find that IRF4 acts in early transitional B cells to restrict marginal zone B cell development, as deletion of IRF4 in mature B cells with CD21-cre impairs plasma cell differentiation but has no effect on marginal zone B cell numbers. These studies highlight IRF4 as the dominant IRF family member in early B lymphopoiesis.


  • Open Access

    Recent Advances in Lupus B Cell Biology: PI3K, IFNγ, and Chromatin

    by Maria A. Bacalao, Anne B. Satterthwaite

    In the autoimmune disease Systemic Lupus Erythematosus (SLE), autoantibodies are formed that promote inflammation and tissue damage. There has been significant interest in understanding the B cell derangements involved in SLE pathogenesis. The past few years have been particularly fruitful in three domains: the role of PI3K signaling in loss of B cell tolerance, the role of IFNγ signaling in the development of autoimmunity, and the characterization of changes in chromatin accessibility in SLE B cells. The PI3K pathway coordinates various downstream signaling molecules involved in B cell development and activation. It is governed by the phosphatases PTEN and SHIP-1. Murine models lacking either of these phosphatases in B cells develop autoimmune disease and exhibit defects in B cell tolerance. Limited studies of human SLE B cells demonstrate reduced expression of PTEN or increased signaling events downstream of PI3K in some patients. IFNγ has long been known to be elevated in both SLE patients and mouse models of lupus. New data suggests that IFNγR expression on B cells is required to develop autoreactive germinal centers (GC) and autoantibodies in murine lupus. Furthermore, IFNγ promotes increased transcription of BCL6, IL-6 and T-bet in B cells, which also promote GC and autoantibody formation. IFNγ also induces epigenetic changes in human B cells. SLE B cells demonstrate significant epigenetic reprogramming, including enhanced chromatin accessibility at transcription factor motifs involved in B cell activation and plasma cell (PC) differentiation as well as alterations in DNA methylation and histone modifications. Histone deacetylase inhibitors limit disease development in murine lupus models, at least in partviatheir ability to prevent B cell class switching and differentiation into plasma cells. This review will discuss relevant discoveries of the past several years pertaining to these areas of SLE B cell biology.


  • Open Access

    Foxo3 Promotes Apoptosis of B Cell Receptor–Stimulated Immature B Cells, Thus Limiting the Window for Receptor Editing

    by Kristina Ottens, Rochelle M. Hinman, Evan Barrios, Brian Skaug, Laurie S. Davis, Quan-Zhen Li, Diego H. Castrillon, Anne B. Satterthwaite

    Central tolerance checkpoints are critical for the elimination of autoreactive B cells and the prevention of autoimmunity. When autoreactive B cells encounter their Ag at the immature B cell stage, BCR cross-linking induces receptor editing, followed by apoptosis if edited cells remain autoreactive. Although the transcription factor Foxo1 is known to promote receptor editing, the role of the related factor Foxo3 in central B cell tolerance is poorly understood. We find that BCR-stimulated immature B cells from Foxo3-deficient mice demonstrate reduced apoptosis compared with wild type cells. Despite this, Foxo3−/− mice do not develop increased autoantibodies. This suggests that the increased survival of Foxo3−/− immature B cells allows additional rounds of receptor editing, resulting in more cells “redeeming” themselves by becoming nonautoreactive. Indeed, increased Igλ usage and increased recombining sequence recombination among Igλ-expressing cells were observed in Foxo3−/− mice, indicative of increased receptor editing. We also observed that deletion of high-affinity autoreactive cells was intact in the absence of Foxo3 in the anti–hen egg lysozyme (HEL)/membrane-bound HEL model. However, Foxo3 levels in B cells from systemic lupus erythematosus (SLE) patients were inversely correlated with disease activity and reduced in patients with elevated anti-dsDNA Abs. Although this is likely due in part to increased B cell activation in these SLE patients, it is also possible that low-affinity B cells that remain autoreactive after editing may survive inappropriately in the absence of Foxo3 and become activated to secrete autoantibodies in the context of other SLE-associated defects.


  • Open Access

    Bruton’s Tyrosine Kinase, a Component of B Cell Signaling Pathways, Has Multiple Roles in the Pathogenesis of Lupus

    by Anne B. Satterthwaite

    Systemic Lupus Erythematosus (SLE) is an autoimmune disease characterized by the loss of adaptive immune tolerance to nucleic acid containing antigens. The resulting autoantibodies form immune complexes that promote inflammation and tissue damage. Defining the signals that drive pathogenic autoantibody production is an important step in the development of more targeted therapeutic approaches for lupus, which is currently treated primarily with non-specific immunosuppression. Here, we review the contribution of Bruton’s tyrosine kinase (Btk), a component of B and myeloid cell signaling pathways, to disease in murine lupus models. Both gain- and loss-of-function genetic studies have revealed that Btk plays multiple roles in the production of autoantibodies. These include promoting the activation, plasma cell differentiation, and class switching of autoreactive B cells. Small molecule inhibitors of Btk are effective at reducing autoantibody levels, B cell activation, and kidney damage in several lupus models. These studies suggest that Btk may promote end organ damage both by facilitating the production of autoantibodies and by mediating the inflammatory response of myeloid cells to these immune complexes. While Btk has not been associated with SLE in GWAS studies, SLE B cells display signaling defects in components both upstream and downstream of Btk consistent with enhanced activation of Btk signaling pathways. Taken together, these observations indicate that limiting Btk activity is critical for maintaining B cell tolerance and preventing the development of autoimmune disease. Btk inhibitors, generally well-tolerated and approved to treat B cell malignancy, may thus be a useful therapeutic approach for SLE.


  • The Role of the Transcription Factor Ets1 in Lupus and Other Autoimmune Diseases

    by Lee Ann Garrett-Sinha, Alyssa Kearly, Anne B. Satterthwaite

    Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by excess B- and T-cell activation, the development of autoantibodies against self-antigens including nuclear antigens, and immune complex deposition in target organs, which triggers an inflammatory response and tissue damage. The genetic and environmental factors that contribute to the development of SLE have been studied extensively in both humans and mouse models of the disease. One of the important genetic contributions to SLE development is an alteration in the expression of the transcription factor Ets1, which regulates the functional differentiation of lymphocytes. Here, we review the genetic, biochemical, and immunological studies that have linked low levels of Ets1 to aberrant lymphocyte differentiation and to the pathogenesis of SLE.


  • Genetic Interaction between Lyn, Ets1, and Btk in the Control of Antibody Levels

    by Jessica Mayeux, Brian Skaug, Wei Luo, Lisa M. Russell, Shinu John, Prontip Saelee, Hansaa Abbasi, Quan-Zhen Li, Lee Ann Garrett-Sinha, Anne B. Satterthwaite

    Tight control of B cell differentiation into plasma cells (PCs) is critical for proper immune responses and the prevention of autoimmunity. The Ets1 transcription factor acts in B cells to prevent PC differentiation. Ets1−/− mice accumulate PCs and produce autoantibodies. Ets1 expression is downregulated upon B cell activation through the BCR and TLRs and is maintained by the inhibitory signaling pathway mediated by Lyn, CD22 and SiglecG, and SHP-1. In the absence of these inhibitory components, Ets1 levels are reduced in B cells in a Btk-dependent manner. This leads to increased PCs, autoantibodies, and an autoimmune phenotype similar to that of Ets1−/− mice. Defects in inhibitory signaling molecules, including Lyn and Ets1, are associated with human lupus, although the effects are more subtle than the complete deficiency that occurs in knockout mice. In this study, we explore the effect of partial disruption of the Lyn/Ets1 pathway on B cell tolerance and find that Lyn+/−Ets1+/− mice demonstrate greater and earlier production of IgM, but not IgG, autoantibodies compared with Lyn+/− or Ets1+/− mice. We also show that Btk-dependent downregulation of Ets1 is important for normal PC homeostasis when inhibitory signaling is intact. Ets1 deficiency restores the decrease in steady state PCs and Ab levels observed in Btk−/− mice. Thus, depending on the balance of activating and inhibitory signals to Ets1, there is a continuum of effects on autoantibody production and PC maintenance. This ranges from full-blown autoimmunity with complete loss of Ets1-maintaining signals to reduced PC and Ab levels with impaired Ets1 downregulation.


  • Open Access

    IL‐21 promotes the production of anti‐DNA IgG but is dispensable for kidney damage in lyn−/− mice

    by Toni Gutierrez, Jessica M. Mayeux, Sterling B. Ortega, Nitin J. Karandikar, Quan‐Zhen Li, Dinesh Rakheja, Xin J. Zhou, Anne B. Satterthwaite

    The autoimmune disease systemic lupus erythematosus is characterized by loss of tolerance to nuclear Ags and a heightened inflammatory environment, which together result in end organ damage. Lyn‐deficient mice, a model of systemic lupus erythematosus, lack an inhibitor of B‐cell and myeloid cell activation. This results in B‐cell hyper‐responsiveness, plasma cell accumulation, autoantibodies, and glomerulonephritis (GN). IL‐21 is associated with autoimmunity in mice and humans and promotes B‐cell differentiation and class switching. Here, we explore the role of IL‐21 in the autoimmune phenotypes of lyn–/– mice. We find that IL‐21 mRNA is reduced in the spleens of lyn–/–IL‐6–/– and lyn–/–Btklo mice, neither of which produce pathogenic autoantibodies or develop significant GN. While IL‐21 is dispensable for plasma cell accumulation and IgM autoantibodies in lyn–/– mice, it is required for anti‐DNA IgG antibodies and some aspects of T‐cell activation. Surprisingly, GN still develops in lyn–/–IL‐21–/– mice. This likely results from the presence of IgG autoantibodies against a limited set of non‐DNA Ags. These studies identify a specific role for IL‐21 in the class switching of anti‐DNA B cells and demonstrate that neither IL‐21 nor anti‐DNA IgG is required for kidney damage in lyn–/– mice.